• Anti-MHC II DRA antibody [EBS-O-111] (STJ16101043)

Anti-MHC II DRA antibody [EBS-O-111] (STJ16101043)

SKU:
STJ16101043

€330.63 - €1,564.38
Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: FC/IHC
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-MHC II DRA is suitable for use in Flow Cytometry and Immunohistochemistry research applications.
Clonality: Monoclonal
Clone ID: EBS-O-111
Conjugation: Unconjugated
Isotype: IgG2ak
Formulation: PBS with 0.02% Sodium Azide.
Purification: Affinity purified from tissue culture.
Concentration: Can be provided as 100 µg/mL, 500 µg/mL or 1mg/mL.
Dilution Range: Flow cytometry (0, 5-1, 0 µg/million cells in 0, 1 ml). Immunohistology (1-2 µg/ml for 30 min at RT; staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 mi
Storage Instruction: Store for up to 1 year at 2-8°C upon receipt.
Gene Symbol: HLA-DRA
Gene ID: 3122
Uniprot ID: DRA_HUMAN
Immunogen: A BALB/c mouse was immunized with RAJI cells. Fusion partner: NS-1.
Tissue Specificity Expressed in professional APCs: macrophages, dendritic cells and B cells (at protein level). Expressed in thymic epithelial cells (at protein level).
Post Translational Modifications Ubiquitinated by MARCHF1 or MARCHF8 at Lys-244 leading to down-regulation of MHCII. When associated with ubiquitination of the beta chain at 'Lys-254', the down-regulation of MHCII may be highly effective.
Function An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance. The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides. The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules.
Protein Name Hla Class Ii Histocompatibility Antigen - Dr Alpha Chain
Mhc Class Ii Antigen Dra
Database Links Reactome: R-HSA-202424
Reactome: R-HSA-202427
Reactome: R-HSA-202430
Reactome: R-HSA-202433
Reactome: R-HSA-2132295
Reactome: R-HSA-389948
Reactome: R-HSA-877300
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Endoplasmic Reticulum Membrane
Early Endosome Membrane
Late Endosome Membrane
Lysosome Membrane
Autolysosome Membrane
The Mhcii Complex Transits Through A Number Of Intracellular Compartments In The Endocytic Pathway Until It Reaches The Cell Membrane For Antigen Presentation
Component Of Immunological Synapses At The Interface Between T Cell And Apc
Alternative Antibody Names Anti-Hla Class Ii Histocompatibility Antigen - Dr Alpha Chain antibody
Anti-Mhc Class Ii Antigen Dra antibody
Anti-HLA-DRA antibody
Anti-HLA-DRA1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance